NanoViricides, Inc.NNVCNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank74
3Y CAGR+34.3%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+34.3%/yr
Quarterly compound
Percentile
P74
Within normal range
vs 3Y Ago
2.4x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 12.65% |
| Q3 2025 | -15.66% |
| Q2 2025 | -8.18% |
| Q1 2025 | 10.89% |
| Q4 2024 | -40.18% |
| Q3 2024 | 63.53% |
| Q2 2024 | -2.68% |
| Q1 2024 | -22.82% |
| Q4 2023 | 7.31% |
| Q3 2023 | -49.65% |
| Q2 2023 | 143.54% |
| Q1 2023 | 2.17% |
| Q4 2022 | 5.22% |
| Q3 2022 | -5.03% |
| Q2 2022 | -6.65% |
| Q1 2022 | -0.49% |
| Q4 2021 | -39.85% |
| Q3 2021 | 32.37% |
| Q2 2021 | 8.19% |
| Q1 2021 | -1.94% |
| Q4 2020 | -5.08% |
| Q3 2020 | 47.44% |
| Q2 2020 | -5.93% |
| Q1 2020 | 12.06% |
| Q4 2019 | -31.73% |
| Q3 2019 | -6.57% |
| Q2 2019 | 21.09% |
| Q1 2019 | -20.96% |
| Q4 2018 | 17.45% |
| Q3 2018 | 12.33% |
| Q2 2018 | 22.12% |
| Q1 2018 | -25.77% |
| Q4 2017 | 19.99% |
| Q3 2017 | -8.27% |
| Q2 2017 | -19.23% |
| Q1 2017 | 23.65% |
| Q4 2016 | -13.16% |
| Q3 2016 | -9.35% |
| Q2 2016 | 50.06% |
| Q1 2016 | -7.38% |